Podcast Summary: Becker Business

Episode: Trends in Physician Practice Management and Urology Investments
Host: Scott Becker
Guest: Amber Walsh, Executive Committee Member at McGuireWoods LLP
Date: August 28, 2025

Overview

In this episode, Scott Becker speaks with Amber Walsh, an executive committee member at McGuireWoods LLP, focusing on current trends in the physician practice management (PPM) industry, with a particular emphasis on urology investments. The discussion explores deal flow, regulatory trends, areas of opportunity within urology, and related specialties. The conversation provides actionable insights for investors, operators, and healthcare professionals interested in the evolving landscape of physician practice management.

Key Discussion Points and Insights

1. State of the PPM Sector

• Increased Caution and Regulatory Scrutiny
  • Over the last 18 months to two years, there has been greater regulatory scrutiny and more intensive due diligence on PPM deals.
  • The sector has shifted from the “super boom” era (2020–2022) to a phase where deals are happening more slowly amid economic and regulatory uncertainty (01:03–02:32).
  • Quote:

    “There's been more, not reluctant, that's not the right word, more caution maybe for private equity investors and debt investors when looking at PPM investments than there had been in the super boom of 2020 through 2022.”
    – Amber Walsh [00:50]

• Market Data
  • Cites Q2 2025 data from Pitchbook and other sources noting that while deals are fewer, activity persists with an emphasis on quality and compliance (01:25–02:32).

2. Urology as an Investment Opportunity

• Recession-Resilient Specialty
  • Urology is viewed as a more "recession-proof" specialty with better reimbursement and a strong mix of preventive, diagnostic, and non-deferrable treatments (02:55–04:05).
  • Quote:

    "A lot of industry stakeholders would describe urology as a little bit more recession proof than some other specialties."
    – Amber Walsh [02:55]

• Ancillary Revenue Streams
  • Urology practices can integrate various ancillary services including ambulatory surgery centers (ASCs), pathology labs, independent pharmacy dispensing, infusion centers, clinical research, radiation therapy, and more (04:05–05:20).
  • These diversifications offer both enhanced care and revenue, plus savings for the healthcare system by keeping certain treatments out of hospitals.
  • Quote:

    "There's a whole host of things that a urology practice can appropriately kind of integrate within the practice... ways to save money for the health care system, keeping some things out of a hospital when appropriate."
    – Amber Walsh [04:50]

3. Urology: Hottest Areas for Practice Profitability

• Oncology and Pharmacy Dispensing
  • Major focus on treatments for genitourinary cancers, alongside clinical research opportunities and in-practice pharmacy dispensing, are lucrative and growing areas (05:55–06:45).
  • Population Demographics:
    • Rising rates of cancer diagnosis and aging population cited (10,000 people turning 65 daily in the US), creating sustained demand.
    • Quote:

      "Some estimates saying, you know, 10,000 people turning 65 every day in the United States. Of course not all of those would receive urological care, but it all is the overlay within urology."
      – Amber Walsh [06:39]

• Evolution of Practice Models
  • Notable trend in the formation and sale of large single-specialty urology groups with private equity backing (e.g., United Urology, created by Audax and sold to One Oncology).
  • Also sees urology integrated into multi-specialty oncology platforms, broadening investment strategies (07:13–07:47).

4. Trends in Other Specialties

• Orthopedics and Women’s Health
  • Ongoing deal activity in orthopedics and some women’s health, with less appetite for purely elective (e.g., cosmetic, derm) specialties during times of economic uncertainty (08:00–08:47).
  • Quote:

    "I think that's where people have a little bit more caution that there's going to be some economic impact. So a little bit less in cosmetics and some of the derm practices, but you still see some interest in those areas too."
    – Amber Walsh [08:21]

• General Sentiment
  • No specialty is off the table, but increased discernment rules current investment decisions (08:35–08:47).
  • Quote:

    “It's just a period of time when there's more discernment is what I would say.”
    – Amber Walsh [08:39]

Notable Quotes & Memorable Moments

• On the cautious investment climate:

  "There's been more caution and the Q2 data... that deals are still happening. There are fewer, they are more cautious, they're taking a little bit longer to get done... because of the state level transactional review processes, the economic uncertainty."
  – Amber Walsh [01:12–01:29]

• Highlighting urology's resilience:

  "Procedures, the care, both the preventive care, the diagnostics and then the treatments are generally not considered to be elective or even things that can really be put off."
  – Amber Walsh [03:30]

• On innovation in urology:

  “There's a lot of innovation and some technology that are opportunities in the space.”
  – Amber Walsh [03:04]

Timestamps for Important Segments

• 00:33 – Amber Walsh’s overview of PPM investment trends
• 02:32 – Discussion shifts to urology’s unique opportunities
• 04:05 – Details on the ancillary opportunities within urology
• 05:55 – Examination of the hottest, most profitable practice areas
• 07:13 – Trends in consolidation and private equity activity in urology
• 08:00 – Activity and outlook in orthopedics, women’s health, and other specialties
• 08:47 – Episode close

Tone and Language

Amber Walsh’s commentary is precise, analytical, and rooted in industry expertise, paired with Scott Becker’s thoughtful, inquisitive hosting. The overall conversation balances data-driven observations with strategic investment analysis, maintaining an informative yet accessible tone throughout.

Summary

This episode of Becker Business offers timely, rich analysis of the evolving physician practice management investment landscape, focusing on why urology remains a standout specialty for growth and innovation despite broader market caution. Listeners gain practical insights into sector dynamics, including regulatory scrutiny, diverse revenue streams, and the impact of demographic trends. Amber Walsh’s discussion provides both granular detail and broader context for anyone interested in the intersection of healthcare, investment, and business development.